218 related articles for article (PubMed ID: 36652960)
1. Comparison of Bisphosphonates Versus Teriparatide in Therapy of the Glucocorticoid-Induced Osteoporosis (GIOP): A Meta-Analysis of Randomized Controlled Trials.
Dong B; Zhou Y; Wang J; Li C; Fu Z; Huang Y; Wang Y; Xu L
Horm Metab Res; 2023 Apr; 55(4):236-244. PubMed ID: 36652960
[TBL] [Abstract][Full Text] [Related]
2. The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden.
Murphy DR; Smolen LJ; Klein TM; Klein RW
BMC Musculoskelet Disord; 2012 Oct; 13():213. PubMed ID: 23110626
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis.
Yuan C; Liang Y; Zhu K; Xie W
J Orthop Surg Res; 2023 Jun; 18(1):447. PubMed ID: 37349750
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of 18 anti-osteoporotic drugs in the treatment of patients with osteoporosis caused by glucocorticoid: A network meta-analysis of randomized controlled trials.
Liu Z; Zhang M; Shen Z; Ke J; Zhang D; Yin F
PLoS One; 2020; 15(12):e0243851. PubMed ID: 33326444
[TBL] [Abstract][Full Text] [Related]
5. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
6. Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: A meta-analysis.
Yuan F; Peng W; Yang C; Zheng J
Int J Surg; 2019 Jun; 66():1-11. PubMed ID: 30890377
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of once-weekly teriparatide in patients with glucocorticoid-induced osteoporosis: the TOWER-GO study.
Tanaka I; Tanaka Y; Soen S; Oshima H
J Bone Miner Metab; 2021 May; 39(3):446-455. PubMed ID: 33211212
[TBL] [Abstract][Full Text] [Related]
8. Head-to-head comparisons of bisphosphonates and teriparatide in osteoporosis: a meta-analysis.
Liu CL; Lee HC; Chen CC; Cho DY
Clin Invest Med; 2017 Jun; 40(3):E146-E157. PubMed ID: 28653616
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D.
Hara T; Hijikata Y; Matsubara Y; Watanabe N
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD013424. PubMed ID: 34231877
[TBL] [Abstract][Full Text] [Related]
10. Effect of bisphosphonates or teriparatide on mechanical complications after posterior instrumented fusion for osteoporotic vertebral fracture: a multi-center retrospective study.
Kawabata A; Yoshii T; Hirai T; Ushio S; Kaito T; Yamashita T; Fujiwara H; Nagamoto Y; Matsuoka Y; Suzuki H; Nishimura H; Terai H; Tamai K; Tagami A; Yamada S; Adachi S; Watanabe K; Katsumi K; Ohashi M; Shibuya Y; Harimaya K; Kawaguchi K; Yokoyama N; Oishi H; Doi T; Kimura A; Inoue H; Inoue G; Miyagi M; Saito W; Nakano A; Sakai D; Nukaga T; Ikegami S; Shimizu M; Futatsugi T; Ohtori S; Furuya T; Orita S; Imagama S; Ando K; Kobayashi K; Kiyasu K; Murakami H; Yoshioka K; Seki S; Hongo M; Kakutani K; Yurube T; Aoki Y; Oshima M; Takahata M; Iwata A; Endo H; Abe T; Tsukanishi T; Nakanishi K; Watanabe K; Hikata T; Suzuki S; Isogai N; Okada E; Funao H; Ueda S; Shiono Y; Nojiri K; Hosogane N; Ishii K
BMC Musculoskelet Disord; 2020 Jul; 21(1):420. PubMed ID: 32611386
[TBL] [Abstract][Full Text] [Related]
11. [Secondary osteoporosis or secondary contributors to bone loss in fracture. Therapeutic strategy for glucocorticoid-induced osteoporosis].
Hayakawa N; Suzuki A
Clin Calcium; 2013 Sep; 23(9):1337-44. PubMed ID: 23999371
[TBL] [Abstract][Full Text] [Related]
12. The efficiency and safety of alendronate versus teriparatide for treatment glucocorticoid-induced osteoporosis: A meta-analysis and systematic review of randomized controlled trials.
Liu ZM; Zhang M; Zong Y; Zhang D; Shen ZB; Guan XQ; Yin F
PLoS One; 2022; 17(5):e0267706. PubMed ID: 35639783
[TBL] [Abstract][Full Text] [Related]
13. Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial.
Sugimoto T; Shiraki M; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Kuroda T; Nakamura T
Curr Med Res Opin; 2013 Mar; 29(3):195-203. PubMed ID: 23259702
[TBL] [Abstract][Full Text] [Related]
14. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
[TBL] [Abstract][Full Text] [Related]
15. Treatment options for glucocorticoid-induced osteoporosis.
Chiodini I; Merlotti D; Falchetti A; Gennari L
Expert Opin Pharmacother; 2020 Apr; 21(6):721-732. PubMed ID: 32004105
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
Hernandez AV; Pérez-López FR; Piscoya A; Pasupuleti V; Roman YM; Thota P; Herrera A
Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908
[TBL] [Abstract][Full Text] [Related]
17. The effects of teriparatide and bisphosphonates on new fractures in postmenopausal women with osteoporosis: A protocol for systematic review and meta-analysis.
Ouyang Y; Chen S; Wan T; Zheng G; Sun G
Medicine (Baltimore); 2021 Feb; 100(7):e24839. PubMed ID: 33607854
[TBL] [Abstract][Full Text] [Related]
18. Comparison between teriparatide and bisphosphonates for improving bone mineral density in postmenopausal osteoporosis patients: A meta-analysis.
Fan G; Zhao Q; Lu P; Chen H; Tan W; Guo W; Liu C; Liu J
Medicine (Baltimore); 2020 Apr; 99(15):e18964. PubMed ID: 32282692
[TBL] [Abstract][Full Text] [Related]
19. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
20. What is new in the treatment of steroid-induced osteoporosis?
Liu RH; Werth VP
Semin Cutan Med Surg; 2007 Dec; 26(4):203-9. PubMed ID: 18395668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]